ST14 and neoplasm: By using multi-transgenic crosses to manipulate expression of ST14/Prss14 and its inhibitor SPINT2, Thomas Bugge's group showed that ST14/Prss14 can initiate tumorigenesis by causing tumor-associated inflammation.